Nanoparticles Targeting Macrophages as Potential Clinical Therapeutic Agents Against Cancer and Inflammation

Guorong Hu1†, Mengfei Guo1†, Juanjuan Xu1, Feng Wu1, Jinshuo Fan1, Qi Huang1, Guanghai Yang2, Zhilei Lv1, Xuan Wang1 and Yang Jin1*

1 Key Laboratory of Respiratory Diseases of the Ministry of Health, Department of Respiratory and Critical Care Medicine, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, China. 2 Department of Thoracic Surgery, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, China

With the development of nanotechnology, significant progress has been made in the design, and manufacture of nanoparticles (NPs) for use in clinical treatments. Recent increases in our understanding of the central role of macrophages in the context of inflammation and cancer have reinvigorated interest in macrophages as drug targets. Macrophages play an integral role in maintaining the steady state of the immune system and are involved in cancer and inflammation processes. Thus, NPs tailored to accurately target macrophages have the potential to transform disease treatment. Herein, we first present a brief background information of NPs as drug carriers, including but not limited to the types of nanomaterials, their biological properties and their advantages in clinical application. Then, macrophage effector mechanisms and recent NPs-based strategies aimed at targeting macrophages by eliminating or re-educating macrophages in inflammation and cancer are summarized. Additionally, the development of nanocarriers targeting macrophages for disease diagnosis is also discussed. Finally, the significance of macrophage-targeting nanomedicine is highlighted, with the goal of facilitating future clinical translation.

Keywords: macrophages, nanoparticles, drug delivery, inflammation, tumor

INTRODUCTION

Macrophages are components of innate immunity and are divided into two types according to their phenotype and function, classically activated macrophages (M1 macrophages), and alternatively activated macrophages (M2 macrophages), that secrete multiple cytokines and express respective surface markers after polarization (1). M1 macrophages express the markers CD86, nitric oxide synthase (NOS) 2, tumor necrosis factor (TNF)-α, and IL-1β. In addition, M2 macrophages highly express the scavenger receptors CD163 and CD200R and release IL-10 (2). M1 macrophages mainly mediate pro-inflammatory processes that protect against the invasion of foreign bodies and play important roles in antitumor immunity in the tumor microenvironment (TME). Furthermore, M2 macrophages possess anti-inflammatory activity in inflammatory diseases but have also been shown to develop protumor characteristics and promote tumor growth and metastasis (3, 4).
Macrophages existing in the TME are also called tumor-associated macrophages (TAMs), which suppress antitumor immunity (5). Mononuclear cells in the blood migrate to the tumor site and transform into TAMs, whose phenotype is similar to that of M2 macrophages (2, 6, 7). Therefore, novel therapeutics targeting M1 macrophages in inflammation and M2 macrophages in cancer that efficiently cure these diseases are desirable strategies that should be developed.

Nanomedicine, which has been used in the generation of therapeutic agents, is anticipated to help researchers solve more clinical problems. Drug delivery systems based on nanoparticles (NPs) have been widely used after several decades of technological developments (8). NPs constitute a large family of materials; synthetic NPs with various structures have been produced using a wide range of materials, including liposomes (9, 10), chitosan (11), poly(lactic-co-glycolic acid) (PLGA) (12, 13), dextran (14), silica (15), and metals such as iron oxide or gold (16). These materials share several features, including their size range, hydrophilic properties and charge characteristics, which allow them to function as carriers for the delivery of drugs. Moreover, the use of NPs as drug carriers is a novel method to treat certain diseases and has several advantages. First, synthetic nanoscale materials, which are non-human components, are usually avirulent and can easily be formed into capsules and films. Second, NPs can penetrate physiological barriers, such as the blood-brain barrier (17), because of their small diameter and sufficient design, which enable their stability in circulation. Third, NPs and their drug loads can be co-encapsulated stably with high consistency. Fourth, NPs can carry engineered (polymeric NPs) antibodies or aptamers based on the target, which enables them to recognize specific cells. These features all support the use of NPs for drug delivery (8, 12, 18).

In this review, we first discuss the properties of NPs as drug carriers. We then introduce the selection of nanomaterials based on clinical need and the benefits of using nano drugs to treat clinical diseases. Afterwards, we highlight the dual roles of macrophage subtypes in inflammation and cancer. The negative impacts of macrophages are mostly attributed to M1 macrophages that modulate inflammation and M2 macrophages that contribute to cancer. Finally, we illustrate how NPs act as carriers to deliver therapeutic agents to macrophage subtypes in a targeted manner to cure inflammation and cancer.

NPs as Potential Therapeutic Agents

Types and Characteristics of NPs

NPs are tiny particles (smaller than 100 nanometers) made of materials such as latex, polymers, ceramic particles, metal particles, and carbon particles. NPs are increasingly being used in medical applications due to their physicochemical properties, including their chemical composition, size, shape, structure, morphology, and surface properties (Figure 1). Their surfaces are hydrophilic or hydrophobic and exhibit surface charge and specific ligands, which are reference factors for the selection of nanomaterials used to treat clinical diseases (19). Therefore, NPs play an active role in transporting drugs to the targeted cell and constitute a drug delivery system. Different NPs have been studied by scientists to explore their value for clinical applications.

Basis for NPs as Carriers of Therapeutic Agents

When selecting materials for NPs designed to carry therapeutic agents, several limitations of traditional drugs, such as their non-specific distribution, potential toxicity, lack of targeting capability, poor solubility in water and low therapeutic index, need to be taken into account and overcome. NPs must produce metabolites or degradation products that do not harm the human body or are decomposed and eliminated by the body. The degradation products of PLGA-NPs, a relatively mature NP that is currently being explored, are lactic acid and hydroxyacetic acid, which are also byproducts of human metabolic pathways, suggesting that PLGA-NPs can be used in medical applications as a biological material that does not produce toxic side effects. This method has been widely used in the field of biomedicine. Bowerman et al. used PLGA-docetaxel-NPs to treat breast cancer and examined their biodegradability and biocompatibility (20).

Additionally, therapeutic agents loaded into NPs must be designed with optimal sizes, shapes, and surface properties to improve their biodistribution, increase their solubility, enhance their stability, and reduce their immunogenicity (19). For instance, silica-NPs are important nanometer materials, and mesoporous silica NPs (MSNs) are currently being widely investigated. These NPs are non-toxic, tasteless, and do not produce pollution levels similar to those of non-metallic materials, and their high absorptivity and good plasticity make them suitable for disease treatment in the medical field. However, the exploitation of MSNs is currently limited to mouse models for preclinical testing, and the metabolism of silica-NPs is still a problem that hinders successful clinical translation and needs to be researched more deeply (21). In the study by Lu et al., silica was developed into MSNs that were loaded with the antitumor drug oxaliplatin and a specific indoleamine 2,3-dioxygenase inhibitor, which increased the drug concentration at the targeted orthotopic pancreatic ductal adenocarcinoma site in mouse models (22). In the studies by Man et al. and Patel et al., Au-NPs were designed to act as a bidentate ligand to enhance the stability of N-heterocyclic carbene (NHC) ligands (23), and liposomes were exploited for packaging non-water soluble drugs because of their excellent water solubility. These NPs are relatively efficient carriers of short genetic sequences that directly insert genes into cells for assembly (24). A recent phase III trial investigating a lipid NPs (LNPs) siRNA formulation to treat transthyretin (TTR)-induced amyloidosis was successful. Optimized ionizable cationic lipids are a significant factor for the clinical success of LNPs-siRNA. LNPs are the most advanced delivery vehicle, and the Food and Drug Administration (FDA) approved LNPs for the treatment of the hereditary condition TTR-mediated amyloidosis in 2018. Currently, numerous ionizable lipids are available for packaging nucleic acids, which are under clinical investigation for the treatment of various diseases, including cancer, and viral infections (25).

Moreover, designing appropriate NPs for different environments is crucial. For instance, altered pH dynamics, leaky vasculature, and hypoxia are major features in the TME.
Nano drugs for acidic environments should be developed to suit different pathophysiological conditions, such as the spatial variations in the TME pH. Chitosan molecules contain free amino acids, can easily form salts in acidic solutions and are cationic, making them useful as drug carriers for antitumor drugs in an acidic TME and for drug release after degradation (11).

Clinical Application Prospects of Nano Drugs
Compared to traditional treatments, nano drugs are more beneficial for the treatment of clinical diseases. First, these drugs have an extended plasma half-life in systemic circulation and a prolonged pharmaceutical effect due to their stability in harsh environments, such as the high levels of proteases or other enzymes in the blood stream and the highly acidic environment in the stomach (26). Second, they can alleviate systemic side effects due to their unique mode of drug delivery, which is cell- (such as macrophage) or tissue-specific, and the treatment efficacy can be maximized (27). Finally, nano drugs can control drug release over a manageable period at precise doses (28). Nanomaterials can be combined into groups with different properties to carry different medications for combination therapy, which has the potential to overcome multidrug resistance (19, 29). With the technological development of drug-loaded NPs, the pharmacokinetics and bioavailability analyses of nano drugs indicate that they exhibit characteristics such as vascular permeability, slowed excretion, and mononuclear phagocyte uptake, which is important in the application of NPs-mediated drug delivery systems for disease treatment (30).

The application of these nanomaterials in their respective fields plays a very strong role, and these nanomaterials were designed to emphasize biological compatibility and biodegradable properties. However, we must admit that due to the complex internal environment in the body, most studies performed to date are verified in only animal models, and few are registered in clinical research. Therefore, the application of these materials in clinical medicine needs further research.

Macrophages Play Different Roles in Inflammation and Cancer
Macrophages originate from hematopoietic stem cells in bone marrow, present in the blood as monocytes that migrate to tissues and differentiate into mature macrophages of different types under the stimulation of different environments in the body (Figure 2). Different macrophage subtypes have diverse activities in inflammation and cancer. M1 macrophages are key components of inflammation, and they exert their proinflammatory functions by producing high levels of proinflammatory cytokines, reactive oxygen species, inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, and reactive nitrogen species. In addition, they also secrete cytokines such as TNF-α, IL-23, IL-1β, and IL-12, which lead to dysfunctional inflammatory responses that develop into conditions characterized by refractory or severe chronic inflammation, such as rheumatoid arthritis (RA) (31), metabolic syndrome-associated disorders (including type 2 diabetes and atherosclerosis), osteoarthritis, asthma, Crohn’s disease, and Alzheimer’s disease (32, 33).

Thus, decreasing proinflammatory cytokine levels at the source may effectively mitigate inflammatory diseases. M1 macrophages play a role in not only proinflammatory immunity but also antitumor immunity, and they play a protective role in tumorigenesis by promoting and amplifying Th1-type responses (34) and secreting a series of cytokines, including TNFs, growth inhibitors, and antiangiogenic factors. Therefore, M1 macrophages have potential applications as active biocarriers for anticancer drug delivery to tumors.

M2 macrophages participate in antineoplastic immunity by increasing the number of suppressor cells among myeloid-derived suppressor cells (MDSCs), TAMs, and immature monocytes. Macrophages in tumors, also called TAMs, comprise 50% of the TME population and contribute to tumor progression and poor prognosis (35–38). In addition, the percentage of

**FIGURE 1** | Summary of the fundamental features of NPs as carriers for drug delivery.
FIGURE 2 | The origin and polarization of macrophages. Tissue macrophages are derived from hematopoietic stem cell (HSC) progenitor cells and exist in blood as monocytes under homeostatic conditions. Monocytes migrate into tissue and differentiate into different macrophages induced by physiologic stimuli, which are associated with a response to inflammatory and cancer conditions.

TAMs is inversely proportional to the survival period, i.e., higher TAM numbers are correlated with shorter tumor patient survival (39). Furthermore, M2 macrophages secrete cytokines such as IL-4 or IL-10, IL-13, VEGFs, and TGF-β to participate in the anti-inflammatory response. The effects of macrophages on tumors and inflammation are shown in Figures 2, 3. Based on the dual role of macrophages, nano drugs mainly target negative macrophages in different diseases, delivering relevant drugs to localized areas to change the polarization conditions, thereby leading to a positive conversion between macrophage subtypes.

Although NPs development is progressing quickly, many obstacles, and challenges remain regarding NPs drug delivery systems, which we will now discuss. The first problem that should be addressed is the mononuclear phagocyte system (MPS), which is a family of cells, including bone marrow precursors, blood monocytes, and tissue macrophages (40). The MPS enables the elimination of NPs through phagocytosis. Interestingly, Rodriguez et al. attached “don’t eat-me” marker CD47 “self” peptides to the surface of NPs to avoid phagocytosis. As part of the MPS, macrophages become the popular target for its passivity, representing a potential area for elucidating more macrophage-targeting therapeutic methods. After MPS phagocytosis, NPs will enter the blood circulation and must then be cleared (41). Many solutions have been proposed to circumvent this problem, such as the novel multistage delivery vector (MSV) proposed by Blanco et al. aimed at successful delivery in the blood vessel (42, 43). NPs cannot exert their therapeutic effects, involving extravasation, cellular membrane traversal and cellular internalization, until they reached their intended target (44). As the mechanism of NPs drug delivery systems becomes increasingly clear, these obstacles need to be further researched to develop different methods for modifying NPs that can overcome these obstacles.

**Strategies for Targeting M1 Macrophages by NPs to Treat Inflammation**

**Depletion of M1 Macrophages**

Based on the negative effect of M1 macrophages on inflammation caused by large numbers of macrophages accumulating at the lesion site, leading to imbalanced inflammation, strategies targeting M1 macrophages in the inflamed tissue with drug-loaded NPs are desirable. In this section, drug-loaded NPs targeting M1 macrophages in the inflammatory environment are discussed. Furthermore, macrophages can quickly and directionally migrate to pathological sites where specific chemokines are being secreted, which allows them to serve as vehicles for the targeted delivery of drugs (45). The strategies of NPs targeting M1 macrophages by delivering specific ligands are illustrated in Figure 4. Two methods currently exist for targeting macrophages: macrophage depletion by NPs-loaded drugs and macrophage re-education by NPs carrying specific cytokines to the microenvironments (46). Thus, in inflammatory disorders, downregulating M1, or repolarizing M1 macrophages to M2 macrophages are two major approaches to relieve inflammation. One example is to use NPs composed of poly(lactic acid)-poly(ethylene glycol) block copolymer (PLA-PEG) to deliver a TNF-α siRNA to M1 macrophages in the model of inflammatory bowel disease (IBD). NPs have been shown to be more powerful and efficient when the Fab’ portion of the F4/80 Ab (Fab’-bearing) is grafted onto the NPs surfaces and to attenuate colitis more effectively (47). Interestingly, although LNPs have been extensively studied as delivery systems for nucleic acid therapy, there are also several reports of their application in IBD therapy and targeting macrophages in particular. Recently, Veiga et al. (48) used the Anchored Secondary scFv Enabling Targeting (ASSET) platform to fabricate mRNA-loaded LNPs, which targeted gene expression in Ly6C+ inflammatory leukocytes. The authors then determined the potential therapeutic efficacy...
Hu et al. Strategies for Nano-Drugs Targeting Macrophages

FIGURE 3 | Macrophage subtypes play different roles in inflammation and cancer. In response to various stimuli, such as inflammation, M1 macrophages promote the progression of inflammation, while M2 macrophages mainly play an anti-inflammatory role. Nevertheless, M1 macrophages are mainly involved in antitumor immunity, while M2 macrophages promote tumor growth and invasion in the tumor microenvironment (TME). The dynamic balance between M1 and M2 macrophages jointly determines the evolution of inflammation and tumors.

Increasing evidence has shown that macrophages, which produce proinflammatory cytokines such as TNF-α that are conducive to disease progression and/or maintenance, play an important role in the pathogenesis of chronic inflammation. Therefore, TNF-α has become a popular target for IBD therapy. Xiao et al. successfully synthesized a macrophage-targeted bioreducible PPM conjugate and utilized it to fabricate NPs carrying sodium triphosphate (TPP) and siRNA by electrostatic interaction. Macrophages can efficiently assimilate these NPs and release high-level RNAi, which decreases TNF-α expression and exerts anti-inflammatory effects in vitro and ex vivo (49). Aouadi et al. developed β1,3-D-glucan-encapsulated siRNA particles (GeRPs) as delivery vehicles that silence genes of mouse macrophages. GeRPs can inhibit the production of TNF-α and IL-4 in macrophages by silencing Map4k4, an unknown mediator of cytokine expression in macrophages (50).

In a recent study by Bejerano et al., miRNA-21-loaded NPs delivered miRNA-21 to cardiac M1 macrophages after myocardial infarction and subsequently increased angiogenesis, reduced the number of apoptotic cells, and improved cardiac healing by downregulating the expression of TNF-α and iNOS. This study highlighted a new therapeutic strategy to target M1 macrophages using the NPs-mediated delivery of miRNA-21 to resolve inflammation (51). These methods directly target M1 macrophages with nano drugs to decrease the levels of proinflammatory cytokines and have been proven to be an effective strategy to treat diseases in preclinical model (52). This NPs-based approach should significantly benefit patients suffering from inflammatory diseases when the technology is applied clinically in the future.

Re-education of M1 Macrophages

Another novel treatment strategy for chronic inflammatory diseases is repolarizing macrophages from an M1 to an M2 phenotype (Figure 4). RA, an autoimmune disease, manifests as the accumulation of macrophages in the arthritic synovium, which limits drug access and renders RA difficult to treat. Jain et al. attempted to encapsulate the anti-inflammatory (IL-10) cytokine encoding plasmid DNA into non-condensing alginate NPs and then modify the tuftsin peptide to the surface of the nanocarriers to actively target macrophages. This technology enabled nano drugs to easily enter the arthritic synovium to...
deliver drugs to macrophages and successfully reprogrammed the macrophage phenotype from M1 to M2, which led to the downregulation of proinflammatory cytokine (IL-6, IL-1β, and TNF-α) expression in systemic and joint tissues and eventually prevented the progression of inflammation and joint damage in arthritic rat models (53).

Importantly, NPs expressing targeting ligands themselves or the addition of targeting ligands to the surface enables NPs to specifically target cells through selective binding to the receptors overexpressed on the cell surface. Dextrin may serve as a representative targeting molecule and has been applied as a plasma volume expander in clinical applications due to its high biocompatibility. The development of nanotechnology has increased the potential applications of dextran for the treatment of inflammatory diseases through the synthesis of dextran-NPs that can target macrophages (14). The selective and high efficiency of dextran-NPs at targeting macrophages is due to the expression of dextran-binding C-type lectins and scavenger receptors on their surface, and these NPs are excreted due to metabolic processing (18). Jain et al. already developed novel carriers to transport IL-10 into inflammatory environments to repolarize macrophages from an M1 to an M2 state, which could serve as a novel therapeutic strategy for the treatment of chronic inflammatory diseases (53). Polyethylenimine NPs carrying the gene for CD163 (an M2 macrophage marker) grafted with a mannose ligand can target cells with a monocytic origin, especially M1 macrophages, thereby converting M1 macrophages into M2 macrophages, leading to the release of anti-inflammatory factors to resolve inflammation and the alleviation of inflammatory disease progression (54). Overall, nano drugs are a novel platform for clinical treatments.

**Tactics for Using NPs to Target M2 Macrophages in Cancer Treatment**

Depletion of TAMs

In regard to TAM targeting, strategies can be divided into two categories: depletion of TAMs and reprogramming of TAMs (55, 56; Figure 5). Advanced methods to deplete TAMs include the inhibition of colony-stimulating factor 1 (CSF1)–CSF1 receptor (CSF1R) signaling, which contributes to the apoptosis of a large proportion of TAMs (57). Many clinical treatment strategies that target CSF1R have been developed, including the employment of small molecules and anti-CSF1R mAbs, and are summarized in Muhammad Ovais’ review (58). Another approach to deplete TAMs is blocking the recruitment of circulating inflammatory monocytes to the tumor site. This process is highly dependent on CC-chemokine ligand 2 (CCL2)–CC-chemokine receptor 2 (CCR2) signaling. By inhibiting the CCL2–CCR2 signaling pathway, mononuclear cells remain in the bone marrow, which leads to a decrease in recruitment to tumor primary and metastatic lesions (59–62). Preclinical trials on the CCL2–CCR2 blockade approach are ongoing. Anti-CCL2 antibodies in combination with chemotherapeutics were proven to be effective for advanced metastatic prostate cancer in murine models (63). In addition, a small molecule CCR2 inhibitor (PF-04136309) was applied in a preclinical pancreatic cancer mouse model, which resulted in reduced tumor growth and fewer liver metastases by reducing the recruitment of inflammatory monocytes to the tumors (64).

Recent research suggests that TAMs hinder antitumor therapies by expressing PD-1 and inhibiting acquired immunity, like T cells, as well as by inhibiting innate immunity, similar to macrophages. TAMs that produce PD-1 and exhibit poor phagocytosis are much worse at engulfing tumor cells (65).
addition, the TME downregulates CD47 expression on TAMs, and this molecule was recently shown to be involved in an immune checkpoint. Thus, immunotherapies targeting TAMs are very promising strategies for fighting cancer along with current immunotherapies, including chimeric antigen receptor T cell therapy (CAR-T), T cell receptor therapy (TCR-T), cytotoxic T lymphocyte-associated protein (CTLA)4 antibody therapy, programmed death (PD)-1 therapy, and programmed death-ligand (PD-L)1 antibody therapy (66). Furthermore, paclitaxel is currently one of the best natural anticancer drugs and has been developed as a nano drug and approved for clinical use in the treatment of breast cancer, ovarian cancer, and lung cancer. Paclitaxel-loaded NPs can penetrate tumor microvessels in solid tumors via binding a high-affinity LFA-1 I domain with cross-linked amphiphilic copolymers. The LFA-1 I domain can specifically identify ICAM-1, which is overexpressed in inflammatory and neoplastic conditions in areas such as the vasculature and TAMs. The amphiphilic copolymer acts as a drug carrier due to its hydrophilic corona, which produces stability, and its hydrophobic core, which allows encapsulation of paclitaxel because it is not highly soluble in water. Ultimately, nano drug delivery of paclitaxel targets markers prevalent in carcinomas and an inflamed TME, such as TAMs (67). In 2019, Rybakova et al. (68) used an in vitro-transcribed mRNA (IVT-mRNA) system for the in vivo delivery of a humanized anti-HER2 (also known as ERBB2) antibody, trastuzumab, and packaged IVT-mRNA into LNPs. This approach not only ensures anticancer activity and efficient in vivo delivery but also delays degradation of the mRNA (68).

Rafique et al. encapsulated calcitriol into LNPs and developed near-infrared calcitriol PEGylated NPs [PEG-LNP(Cal)] by a microfluidic mixing technique. The results showed that calcitriol can be effectively targeted to macrophages (69). Nanotechnology systems for the targeted delivery of drugs to TAMs are effective methods for mitigating tumor promotion (46). These systems also substantially increase the efficiency of chemotherapy and overcome drug resistance in treating cancer (70).

**Re-education of TAMs**

TAMs are responsible for tumor promotion and malignant tumor development, which is usually associated with poor prognosis. Because TAMs are highly plastic, reprogramming these cells toward a tumoricidal phenotype has been a popular therapeutic strategy. TAMs promote tumor development through the secretion of immunosuppressive agents. Therefore, TAMs are potential targets for cancer therapy by nano drugs that can reprogram TAMs into antitumorigenic macrophages (71). Reprogramming of TAMs, also called re-education of TAMs, is currently the most attractive strategy for cancer treatment and can reverse the protumor phenotype into the antitumor phenotype (55, 58). This method can slow or stop cancer growth by activating the antitumor functions of M1 macrophages and stimulating the activity of Th1-type cytotoxic T cells and other effector cells (72). In recent years, more researchers have focused on small molecules and NPs formulations for macrophage repolarization, such as Toll-like receptor (TLR) agonists, cytokines, antibodies, and RNAs (73). In addition to the polarization methods
mentioned, we summarize the common polarization targets in Table 1. Here, we describe some specific studies that have been performed regarding TAM depolarization. Polymeric NPs have been designed and used with an IL-12 payload to re-educate TAMs, eventually promoting macrophage conversion from the M2 to the M1 phenotype, demonstrating the promise of nanomaterials as a platform for cancer immunotherapy (78). TLR agonists are a potential method to polarize TAMs into M1-like cells (82). NPs loaded with TLR agonists targeting TAMs are currently being used as antitumor agents in animal models. In 2018, Rodell et al. established that R848-loaded β-cyclodextrin NPs (CDNP-R848) contributed to efficient drug delivery to TAMs. The authors capitalized on β-cyclodextrin (CD), which enables drug solubilization, and R848, an agonist of TLR7 and TLR8 that can target TAMs and eventually shift TAMs to an M1 phenotype, thereby improving cancer immunotherapy and controlling tumor growth. This method has been utilized in animal models, protecting the animals against tumor rechallenge and improving immunotherapeutic responses when used in combination with the immune checkpoint inhibitor anti-PD-1. This treatment strategy represents a tool to transform TAMs into an M1-like phenotype and subsequently promote tumor regression and increase the efficacy of immune checkpoint blockade (83, 84). Another successful example is the encapsulation of miR-125b into CD44 targeting hyaluronic acid-poly(ethyleneimine) (HA-PEI)-based NPs by Parayath et al. After abundant scientific experiments, the authors determined that this type of NPs successfully enables the transfection of TAMs and demonstrated its contribution to TAM repolarization in anticancer immunotherapy (85).

More than that, carbohydrates like mannose can also employ to target macrophages. The expression of mannose receptors in the cells of the immune system was preferential which made mannose become a popular ligand targeting macrophages (86). Lots of new methods using mannose as targeting ligand have been proposed in recent months. Wang et al. developed twin-like core shell NPs (TCSN) for targeting delivery of sorafenib and TAMs re-polarization agents IMD-0354 to cancer cells and TAMs which could enhance tumor-localized chemoimmunotherapy. Mannose, as a targeting ligand was anchored to IMD-0354 for selective targeting delivery to TAMs (87). Zhao et al. synthesized the albumin NPs modified with dual ligands, a transferrin receptor (TfR)-binding peptide T12 and mannose. They proved that this system efficiently inhibited the glioma cell proliferation and successfully “re-educated” the protumor M2 toward antitumor M1 (88). Most of mannose as ligand targeting macrophages now are applied for macrophage re-polarization. It is helpful and of great potential to be used in tumor-localized chemoimmunotherapy. Additionally, TAMs can activate the nuclear factor (NF)-κB pathway by producing ligands to target protumor genes such as CXCL12 and VEGFC via the CD40 receptor (89). Interestingly, CD40 blockage also leads to the upregulation of IL12, which can repolarize TAMs into M1 macrophages. For instance, NPs loaded with a corresponding inhibitor can block the NF-κB signaling pathway, which can switch TAMs into M1 macrophages that are toxic to tumor cells; this approach has a bright future in cancer treatment (90). Additionally, for successful nanocarrier drug delivery to macrophages, different drugs and their individual physicochemical properties should be considered. The encapsulation strategies, including the covalent stimulus-responsive covalent linking of drugs to the carrier and different release rates, are summarized in Table 2. In all, NPs deliver specific ligands to M2 macrophages to modulate the function in tumors, as summarized in Figure 5.

| Target | Signaling pathway | Clinical effects | References |
|--------|-------------------|------------------|------------|
| TLR    | NF-κB/IRF3        | TLR agonists are commonly used, such as in the treatment of malignant pleural effusion (MPE) in advanced lung cancer patients | (74, 75) |
| CSF1   | NF-κB/EPK1/2      | Anti-CSF-1 therapy improved antitumor efficacy | (76) |
| CD40   | NF-κB             | Anti-CD40 combined with imatinib has clinical potential for the treatment of GIST | (77) |
| IL12   | Jak2/Stat4        | IL12 is applied for NPs | (78) |
| TREM-1 | TREM-1/DAp12/Syk  | TREM-1 plays a crucial role in regulating IL-22 production by ILC3 through modulating M1 macrophage polarization during DSS-induced acute colitis | (79) |
| BTK    | Blocks BTK        | BTK inhibitor is targeted to leukemia in NPs | (80) |
| COX2   | Blocks PI3K/Akt    | COX2 inhibitor is approved for leukemia | (81) |

Table 1 | Summary of the common polarization targets of TAMs.
Although advanced cancer research has revealed that the TME affects cancer progression and metastasis (71), some specific TME conditions could be used to promote NPs uptake by TAMs in tumors. For example, the enhanced permeability and retention (EPR) effect is a typical characteristic of the TME (114). EPR may be related to the difference between tumor vasculature and normal blood vessels, with leaky capillary gaps of the former being ~100–780 nm and those of the physiological blood vessels being ~5–8 nm (115–117). Many studies have shown that NPs accumulate more in tumors than in other tissues due to the heterogeneity of the tumor vasculature and EPR effects. In addition, the half-life of the drug in the NPs system is prolonged for escapement from renal clearance (118). These two conditions, which encompass the blood circulation stability of NPs and the EPR effect, provide an avenue for drugs to reach and combat tumors. The EPR effect makes NPs extravasate from the tumor vasculature and transport into tumor tissues due to the heterogeneity of the tumor vasculature and normal blood vessels, with leaky capillary gaps of the former being ~100–780 nm and those of the physiological blood vessels being ~5–8 nm (115–117). Many studies have shown that NPs accumulate more in tumors than in other tissues due to the heterogeneity of the tumor vasculature and EPR effects. In addition, the half-life of the drug in the NPs system is prolonged for escapement from renal clearance (118). These two conditions, which encompass the blood circulation stability of NPs and the EPR effect, provide an avenue for drugs to reach and combat tumors. The EPR effect makes NPs extravasate from the tumor vasculature and transport into tumor tissues due to the heterogeneity of the tumor vasculature and normal blood vessels, with leaky capillary gaps of the former being ~100–780 nm and those of the physiological blood vessels being ~5–8 nm (115–117). Many studies have shown that NPs accumulate more in tumors than in other tissues due to the heterogeneity of the tumor vasculature and EPR effects. In addition, the half-life of the drug in the NPs system is prolonged for escapement from renal clearance (118). These two conditions, which encompass the blood circulation stability of NPs and the EPR effect, provide an avenue for drugs to reach and combat tumors. The EPR effect makes NPs extravasate from the tumor vasculature and transport into tumor tissues due to the heterogeneity of the tumor vasculature and normal blood vessels, with leaky capillary gaps of the former being ~100–780 nm and those of the physiological blood vessels being ~5–8 nm (115–117). Many studies have shown that NPs accumulate more in tumors than in other tissues due to the heterogeneity of the tumor vasculature and EPR effects. In addition, the half-life of the drug in the NPs system is prolonged for escapement from renal clearance (118). These two conditions, which encompass the blood circulation stability of NPs and the EPR effect, provide an avenue for drugs to reach and combat tumors. The EPR effect makes NPs extravasate from the tumor vasculature and transport into tumor tissues due to the heterogeneity of the tumor vasculature and normal blood vessels, with leaky capillary gaps of the former being ~100–780 nm and those of the physiological blood vessels being ~5–8 nm (115–117). Many studies have shown that NPs accumulate more in tumors than in other tissues due to the heterogeneity of the tumor vasculature and EPR effects. In addition, the half-life of the drug in the NPs system is prolonged for escapement from renal clearance (118). These two conditions, which encompass the blood circulation stability of NPs and the EPR effect, provide an avenue for drugs to reach and combat tumors. The EPR effect makes NPs extravasate from the tumor vasculature and transport into tumor tissues due to the heterogeneity of the tumor vasculature and normal blood vessels, with leaky capillary gaps of the former being ~100–780 nm and those of the physiological blood vessels being ~5–8 nm (115–117). Many studies have shown that NPs accumulate more in tumors than in other tissues due to the heterogeneity of the tumor vasculature and EPR effects. In addition, the half-life of the drug in the NPs system is prolonged for escapement from renal clearance (118). These two conditions, which encompass the blood circulation

TABLE 2 | Different drug encapsulation strategies.

| Type of drug | Specific drug | Encapsulation strategy | References |
|-------------|--------------|------------------------|------------|
| Metal complex formation | Cisplatin | Cisplatin-loaded polymeric micelles (CDDP-PMs) is supposed to improve encapsulation efficiency. Cisplatin ligands can be replaced with a polymer s carbohydrate group, leading to a stable formulation from which cisplatin can be recovered in physiological conditions. Such a strategy is supposed to improve encapsulation efficiency (vs., for example, that of passive liposomal encapsulation, which does not exceed 18%) | (91–93) |
| In and Ga | Empty liposomes are initially loaded with the chelating agent, and immediately prior to administration, the drug is formed in situ by incubation with another metal complex with a smaller binding constant, leading to 90% encapsulation of In and Ga in liposomes | (91, 94, 95) |
| $^{225}$Ac | $^{225}$Ac is encapsulated by liposomes. After 30 days, $^{225}$Ac retention as high as 81% of the initially encapsulated radioactivity was achieved | (91, 96) |
| Electrostatic interactions | Genetic material | Ionizable amino lipids are used as an alternative to cationic lipids to produce liposomes with improved encapsulation ability. These lipids are cationic at the time of preparation in acidic pH but remain neutral at the time of administration (at physiological pH). One example is the use of 1,2-dioleoyl-3-dimethylammonium propane (DODAP), which markedly changes the encapsulation of oligonucleotides from a mere 5% at 0% DODAP to 80% at 30% DODAP in the lipid mixture at pH 4 | (91, 97) |
| Negatively charged drugs | NPs containing cholesterol and stearlyamine encapsulate high payloads of retinoic acid by ionic interactions. The addition of positively charged stearlyamine remarkably improves the entrapment from 13% (without stearlyamine) to > 90% | (91, 98) |
| Positively charged drugs | Using anionic liposomes containing phosphatidylycerine can improve the encapsulation of cationic drugs such as cisplatin. Positively charged PLGA NPs contain donepezil hydrochloride (DP) that is used as a positively charged hydrophilic drug model. Then the PLGA NPs are coated with chitosan hydroxypropyltrimonium chloride | (91, 92, 99) |
| Zwitterionic and amphiphilic drugs | Polyelectrolytes, such as polyethyleneimine-based polymers, can improve the encapsulation of hydrophobic drugs | (91, 100) |
| Covalent bonding | PTX | Hu et al. prepared carboxyl-terminated diblock copolymers (mPEG-b-PLA) and triblock copolymers (PLA-b-mPEG-b-PLA) and attached paclitaxel (PTX) to their molecular ends. By changing the block lengths of PEG and PLA, the paclitaxel content in the conjugates can be widely adjusted up to 8–15% wt | (91, 101) |
| Hydrogen bonds | 5-Fluorouracil | Bhadra and co-workers successfully synthesized dendronized poly(amide amine) polymers to encapsulate drugs such as 5-fluorouracil. By using this strategy, hydrogels played an important role in improving the efficiency of the drug complexation | (91, 102) |
| Hydrophobic encapsulation | MTX-Oet | Cerqueira et al. produced polyoxyethylene-α-tocopheryl sebacate (PTS) micelles to deliver a hydrophobic derivative of methotrexate, MTX di-ethylated (MTX-OEt). MTX-OEt was efficiently encapsulated onto the produced PTS micelles which preserved its physicochemical properties. This strategy showed a promising intracellular delivery performance with potentiality for cancer therapy | (103) |
| Curcumin | The encapsulation of curcumin (or THC) into thehydroxypropyl (HP)-cyclodextrins (CD) (HP-CDs) significantly increased the drug solubility and enhanced the corneal and retinal epithelial permeability | (104) |
| Astaxanthin | Astaxanthin was loaded in poly(lactic-co-glycolic acid) (PLGA) NPs coating with chitosan oligosaccharides (COS). The encapsulation efficiency (>85%) and loading capacity (>15%) of the astaxanthin in the NPs was relatively high | (105) |
| (±)-α-Tocopherol (TP) | The (±)-α-Tocopherol (TP) with vitamin E activity was encapsulated into biocompatible core-shell structured NPs which were synthesized by poly(lactic acid) (PLA) and poly(lactide-co-glycolide) (PLGA). This encapsulation strategy obtained NPs with a hydrophobic TP core and a polymer shell with high encapsulation efficiency (EE%) (69%) | (106, 107) |
into the immunosuppressive M2 phenotype in an inflammatory environment and repolarizing M2 macrophages into the immunoreactive M1 state in the TME appear to be most effective in different circumstances. In fact, beyond the consumption of M1 macrophages in inflammation and TAMs in cancer, their main disadvantage is the loss of their potential immune stimulatory effects as major phagocytes and specialized antigen presenting cells. Therefore, the functional repolarization of macrophages to enhance their beneficial function and limit their detrimental properties is currently the most attractive strategy for disease treatment.

**Diagnostic Purposes of Targeting Macrophages**

As stated above, targeting different macrophage subtypes by different NPs can efficiently cure inflammation and cancer in animal models. In addition, macrophage targeting might be used for disease diagnosis, especially for malignant lesions, beyond the delivery of TAM-targeting therapeutic drugs by NPs. However, this approach is linked to the design, development, and application of NPs (120). Based on the type of NPs, the PET, CT, MRI imaging modalities, and their combinations can be used to detect the accumulation of NPs in macrophages (121). For example, MRI-compatible nanomaterials, such as iron oxide NPs, can be rapidly recognized and phagocytosed by macrophages, which leads to a positive MR signal effect on T1-weighted MR images, and the signal strength is proportional to the number of macrophages, thereby providing a non-invasive method to assess the progression and prognosis of diseases and facilitating treatment-related decisions by quantifying TAMs in tumors (122). Interestingly, abnormal patterns of NPs accumulation are helpful for the accurate detection of lymph node metastases in prostate cancer, which is judged by unique MRI features (123, 124). The clinical trial (NCT01770353) of MM-398 (nanoliposomal irinotecan, Nal-IRI) assessing the practicability of ferumoxytol by imaging TAMs to predict patient response is currently ongoing. Furthermore, the binding of various molecular markers of macrophage subtypes to NPs surfaces allows specific recognition by macrophages (125). For instance, NPs-labeled Ly-6C<sup>high</sup> monocyte biomarkers are more efficient than their Ly-6C<sup>low</sup> counterparts in mice (126). Therefore, developing non-invasive methods for imaging macrophages holds substantial promise.

**CONCLUDING REMARKS**

In summary, we report the current status of macrophage-targeting NPs in the context of inflammatory disorders and cancers. Together with the facts that macrophages are naturally involved in and crucial for the pathogenesis of inflammation/cancer and that current nanotechnologies can design and generate NPs that specifically target macrophages, the rich variety of examples discussed above makes us confident that well-engineered NPs targeting macrophages demonstrate a new paradigm in a wide range of therapies for cancer and inflammatory disorders, such as acute lung injury, RA, stroke, atherosclerosis and myocardial infarction.

While NPs targeting macrophages have shown potential in disease treatment, many interesting questions and challenges still need to be addressed. First, as we know, the time course of macrophage infiltration is always dependent on the pathogenesis of the disease and its stages; thus, studies on the dynamics of macrophage activation and trafficking in cancer and inflammatory disorders are needed for optimization of the best time to deliver NPs to better target infiltrated macrophages. Second, recent studies have highlighted the complexity and phenotypic heterogeneity of inflammatory monocyte-derived cells or resident macrophage populations in different tissues and disease contexts (127). As their variability extends far beyond the simplistic classifications of M1 and M2 phenotypes, NPs must be engineered to achieve selective targeting by clearly elucidating and differentiating the specific subtypes. Last but not least, due to the heterogeneity of the inflammatory/tumor microenvironment, NPs–cell interactions are also vital mechanisms that must be elucidated. These NPs–cell interactions, including but not limited to the internalization and processing of nanomaterials by macrophages and other immune cells, are only partially understood and play an important role in both therapeutic and imaging efficacy.

Initial data from macrophage-targeted pharmacological interventions in clinical trials indicate that macrophage-targeting strategies can be successfully translated into novel clinical treatment options (128, 129). However, for the clinical translation of NPs-based macrophage-targeting therapies, further work is required to explore the safety of NPs, patient-specific responses, disease-type specificity, and precise targeting/imaging technology to close the gap between the bench and clinic.

**AUTHOR CONTRIBUTIONS**

GH and MG wrote the draft. YJ reviewed and edited the manuscript before submission. JX, FW, JF, QH, GY, ZL, and XW commented and added extra information.

**FUNDING**

This paper was supported by the National Natural Science Foundation of China (nos. 81572942 and 81770096), the State Project for Essential Drug Research and Development, China (no. 2018ZX09301001001), the Natural Science Foundation of Hubei Province (no. 2014CFA057), the Special Fund for Technological Innovation of Hubei (no. 2017ACA094), the Health and Planning Commission Fund of Hubei Province (no. WJ2017M098), the Science and Technology Support Program of Hubei Province (no. YSF2015001294), the Wuhan Planning Project of Science and Technology (no. 20140601010036), and the Special Fund for Industrial Transformation and Upgrading.
REFERENCES

1. Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, Senechal B, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. *Immunity.* (2010) 33:375–86. doi: 10.1016/j.immuni.2010.08.012

2. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. *Nat Rev Immunol.* (2005) 5:953–64. doi: 10.1038/nri1733

3. Murray PJ, Wynn TA. Obstacles and opportunities for understanding macrophage polarization. *J Leukocyte Biol.* (2011) 89:557–63. doi: 10.1189/jlb.0710409

4. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. *Nat Rev Immunol.* (2011) 11:73–27. doi: 10.1038/nri3073

5. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. *Nat Rev Immunol.* (2008) 8:958–69. doi: 10.1038/ nr2248

6. Sutterwala FS, Noel GI, Salgame P, Mosser DM. Reversal of proinflammatory responses by ligation of the macrophage Fcgamma receptor type I. *J Exp Med.* (1998) 188:217–22. doi: 10.1084/jem.188.1.217

7. Mody VV, Siwale R, Singh A, Mody HR. Introduction to nanomedicine. *Nanomedicine.* (2012) 161:505–22. doi: 10.1016/j.jconrel.2012.01.043

8. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. *FASEB J.* (2005) 19:311–30. doi: 10.1096/fj.04-2747rev

9. Nyberg BD, Li J, Kassens HD, Gersappe KL, Gao J, Steinhart T, et al. Multifunctional nanoparticles: an overview of biomedical applications. *J Controlled Release.* (2012) 161:505–22. doi: 10.1016/j.jconrel.2012.01.043

10. Ren H, He Y, Liang J, Cheng Z, Zhang M, Zhu Y, et al. Role of liposome size, surface charge, and PEGylation on rheumatoid arthritis targeting therapy. *ACS Appl Mater Interfaces.* (2019) 11:20304–15. doi: 10.1021/acs.ami.8b02293

11. Rao W, Wang H, Han J, Zhao S, Dumbleton J, Agarwal P, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. *Immunity.* (2010) 33:375–86. doi: 10.1016/j.immuni.2010.08.012

12. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V. PL GA-based targeting therapy. *Angew Chemie Int Ed.* (2011) 50:4653–64. doi: 10.1002/anie.201403036

13. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. *Adv Drug Deliv Rev.* (2011) 63:170–83. doi: 10.1016/j.addr.2010.10.008

14. Ma L, Liu TW, Wallig MA, Dobrucki IT, Dobrucki LW, Nelson ER, et al. Efficient targeting of adipose tissue macrophages in obesity with polysaccharide nanocarriers. *J Pharm Bioall Sci.* (2016) 10:6952–62. doi: 10.1016/j.jpbas.2016.10.007

15. Diab R, Canilho N, Pavel IA, Haffner FR, Girardon M, Pasc A. Silica-based systems for oral delivery of drugs, macromolecules and cells. *Adv Colloid Interface Sci.* (2017) 249:346–52. doi: 10.1016/j.cis.2017.04.005

16. Mody VV, Siwale R, Singh A, Mody HR. Introduction to metallic nanoparticles. *J Pharmacy Bioall Sci.* (2012) 2:889–91. doi: 10.1016/j.jpbas.2012.08.004

17. Pang L, Qin J, Han L, Zhao W, Liang J, Xie Z, et al. Exploiting macrophages as targeted carrier to guide nanoparticles into glioma. *Oncotarget.* (2016) 7:37081–91. doi: 10.18632/oncotarget.9464

18. Pustylnikov S, Sagar D, Jain P, Khan ZK. Targeting the C-type lectin-mediated host-pathogen interactions with dextran. *J Pharm Pharmac.* (2014) 17:371–92. doi: 10.1148/jjp.2014001070

19. Sun T, Zhang YS, Pang B, Huyn DC, Yang M, Xia Y. Engineered nanoparticles for drug delivery in cancer therapy. *Angew Chemie.* (2014) 53:12320–64. doi: 10.1002/anie.201403036

20. Bowerman CJ, Byrne JD, Chu KS, Schorzman AN, Keeler AW, Sherwood CA, et al. Docetaxel-loaded PLGA nanoparticles improve efficacy in taxane-resistant triple-negative breast cancer. *Nano Lett.* (2017) 17:242–8. doi: 10.1021/acs.nanolett.6b03971

21. Kwon D, Cha BG, Cho Y, Min J, Park EB, Kang SJ, et al. Extra-large pore mesoporous silica nanoparticles for directing in vivo M2 macrophage polarization by delivering IL-4. (2017) 17:2747–56. doi: 10.1021/acs.nanolett.6b04130

22. Lu J, Liu X, Liao YP, Salazar F, Sun B. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. *Nat Comm.* (2017) 8:1811. doi: 10.1038/s41467-017-01659-y

23. Man RWY, Li CH, MacLean MWA, Zenkina OV, Zamora MT, Saunders LN, et al. Ultra stable gold nanoparticles modified by bidentate N-heterocyclic carbene ligands. *J Am Chem Soc.* (2017) 140:1576–9. doi: 10.1021/jacs.7b08516

24. Tasciotti E, Liu X, Bhavane R, Plant K, Leonard AD, Price BK, et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. *Nat Nanotechnol.* (2008) 3:151–7. doi: 10.1038/nnano.2008.34

25. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. *Nat Biotechnol.* (2015) 33:941–51. doi: 10.1038/nbt.3330
45. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. (2004) 25:677–86. doi: 10.1016/j.ti.2004.09.015

46. Ngamjenjawong C, Guaslan HH, Pun SH. Progress in tumor-associated macrophage (TAM) targeted therapeutics. Adv Drug Deliv Rev. (2017) 114:206–21. doi: 10.1016/j.addr.2017.04.010

47. Xiao B, Laroui H, Viennois E, Canup BS, Geem D, Denning TL, et al. Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-alpha RNA interference for IBD therapy. Biomaterials. (2013) 34:5471–82. doi: 10.1016/j.biomaterials.2013.06.008

48. Veiga N, Goldsmith M, Granot Y, Rosenblum D, Dammes N, Kedmi R, et al. orally delivered siRNA targeting macrophage Mapk4 suppresses systemic inflammation. Nature. (2009) 458:1180–4. doi: 10.1038/nature07774

49. Bejarano T. Nanoparticle delivery of mrRNA-21 mimic to cardiac macrophages improves myocardial remodeling after myocardial infarction. Nano Lett. (2018) 18:3885–91. doi: 10.1021/acs.nanolett.8b02578

50. Xiao B, Larou H, Ayudhurai S, Viennois E, Charania MA, Zhang Y, et al. Macrophage-targeted delivery systems for nucleic acid therapy of inflammatory diseases. J Control Release. (2014) 190:515–30. doi: 10.1016/j.jconrel.2014.04.021

51. Jain S, Tran TH, Amiji M. Macrophage repolarization with targeted alginate nanoparticles containing IL-10 plasmid DNA for the treatment of experimental arthritis. Biomaterials. (2015) 61:162–77. doi: 10.1016/j.biomaterials.2015.05.028

52. Alvarado-Vazquez PA, Bernal L, Paige CA, Gросick RL, Moracho Viloriales C, Ferreira DW, et al. Macrophage-specific nanotechnology-driven CD163 overexpression in human macrophages results in an M2 phenotype under inflammatory conditions. Immunochemistry. (2017) 222:900–12. doi: 10.1016/j.ymimi.2017.05.011

53. DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. (2019) 19:369–82. doi: 10.1038/s41577-019-0127-6

54. Ostuni R, Kratochvill F, Murray PJ, Natoli G. Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol. (2015) 36:229–39. doi: 10.1016/j.it.2015.02.004

55. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. (2013) 19:1264–72. doi: 10.1038/nm.3337

56. Egawa T, Guo M, Chen C. Tailoring nanomaterials to target colonic macrophages offer an effective therapy for experimental colitis. J Control Release. (2018) 280:206–18. doi: 10.1016/j.jconrel.2017.09.024

57. Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. (2010) 21:41–8. doi: 10.1016/j.cytogfr.2009.11.009

58. Qiu Q, Li C, Song Y, Shi T, Luo X, Zhang H, et al. Targeted delivery of iRibiRNA to tumor-associated macrophages by silic acid-stearic acid conjugate modified nanoparticles for cancer immunotherapy. Acta Biomater. (2019) 92:184–95. doi: 10.1016/j.actbio.2019.05.030

59. Veiga N, Goldsmith M, Granot Y, Rosenblum D, Dammes N, Kedmi R, et al. orally delivered siRNA targeting macrophage Mapk4 suppresses systemic inflammation. Nature. (2009) 458:1180–4. doi: 10.1038/nature07774

60. Xiao B, Larou H, Ayudhurai S, Viennois E, Charania MA, Zhang Y, et al. Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-alpha RNA interference for IBD therapy. Biomaterials. (2013) 34:5471–82. doi: 10.1016/j.biomaterials.2013.06.008

61. Oveis M, Goldsmith M, Granot Y, Rosenblum D, Dammes N, Kedmi R, et al. Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes. Nat Commun. (2018) 9:4493. doi: 10.1038/s41467-018-06936-1

62. Qiu Q, Li C, Song Y, Shi T, Luo X, Zhang H, et al. Targeted delivery of iRibiRNA to tumor-associated macrophages by silic acid-stearic acid conjugate modified nanoparticles for cancer immunotherapy. Acta Biomater. (2019) 92:184–95. doi: 10.1016/j.actbio.2019.05.030

63. Veiga N, Goldsmith M, Granot Y, Rosenblum D, Dammes N, Kedmi R, et al. orally delivered siRNA targeting macrophage Mapk4 suppresses systemic inflammation. Nature. (2009) 458:1180–4. doi: 10.1038/nature07774

64. Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res. (2013) 19:3404–15. doi: 10.1159/000345323

65. Gordon SR, Maute RL, Dulkens BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immuinity. Nature. (2017) 545:495–9. doi: 10.1038/nature22396

66. Tseng D, Volker NP, Willingham SR, Contreras-Trujillo H, Fathman JW, Fernhoff NB, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci USA. (2013) 110:11103–8. doi: 10.1073/pnas.1305569110
Na YR, Yoon YN, Son D, Jung D, Gu GJ, Seok SH. Consistent inhibition of cyclooxygenase-2 drives macrophages towards the inflammatory phenotype. *PLoS ONE.* (2015) 10:e0118203. doi: 10.1371/journal.pone.0118203

Shiue H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Iwakura Y, et al. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. *Proc Natl Acad Sci USA.* (2012) 109:2066–71. doi: 10.1073/pnas.1113099110

Rodell CB, Arlauckas SP, Cuccarese MF, Garris CS, Li R, Ahmed MS, et al. TLR/7-8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. *Nat Biomed Eng.* (2018) 2:578–88. doi: 10.1038/s41551-018-0236-8

Cully M. Cancer: re-educating tumour-associated macrophages in a genetically engineered nonsmall cell lung cancer model by intraperitoneal administration of hyaluronic acid-based nanoparticles encapsulating MicroRNA-125b. *Nan Lett.* (2018) 18:3571–9. doi: 10.1021/acs.nanolett.8b00689

Irace MJ, Ruan HH, Hamzavi SM, Espuelas S. Mannose-targeted systems for the delivery of therapeutics. *Expert Opin Drug Deliv.* (2008) 5:703–24. doi: 10.1517/17425247.5.6.703

Wang T, Zhang J, Hou T, Yin X, Zhang N. Selective targeting of tumor cells and tumor-associated macrophages separately by twin-like core-shell nanoparticles for enhanced tumor-localized chemotherapy. *Nanoscale.* (2011) 3:1394–46. doi: 10.1039/CN09374B

Zhao P, Wang Y, Kang C, Wu A, Yin W, Tang Y, et al. Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy. *Chem. Sci.* (2018) 9:2674–89. doi: 10.1039/C7CS04853J

Biswas SK, Lewis CE. NF-κB as a central regulator of macrophage function in tumors. *J Leukoc Biol.* (2010) 88:877–84. doi: 10.1189/jlb.0310153

Fong CH, Bebien M, Didierlaurent A, Nebauer R, Hussell T, Broide D, et al. An antifibrotic role for NOX2 through the inhibition of “classical” macrophage activation. *J Exp Med.* (2008) 205:1269–76. doi: 10.1084/jem.20080124

Kita K, Dittrich C. Drug delivery vehicles with improved encapsulation efficiency: taking advantage of specific drug-carrier interactions. *Expert Opin Drug Deliv.* (2011) 8:329–42. doi: 10.1517/17425247.2011.553216

Steerenberg PA, Storm G, de Groot G, Claessen A, Bergers JJ, Franken MA, et al. Liposomes as drug carrier system for cis-diaminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity, and Pt distribution. *Cancer Chemother Pharmacol.* (1988) 21:299–307. doi: 10.1007/BF00264195

Chen Q, Luo L, Xue Y, Han J, Liu Y, Zhang Y, et al. Liposomal polymeric complex micelles with a modulated drug/copolymer ratio for improved in vivo performance. *Acta Biomater.* (2019) 92:205–18. doi: 10.1016/j.actbio.2019.05.007

Beaumier PL, Hwang KJ. An efficient method for loading indium-111 into liposomes using acetylacetone. *J Nucl Med.* (1982) 23:810–5.

Hwang KJ, Merriam JE, Beaumier PL, Luk KF. Encapsulation, with high efficiency, of radioactive metal ions in liposomes. *Biochim Biophys Acta.* (1982) 716:101–9. doi: 10.1016/S0005-2760(82)80207-0

Chang MY, Seideman J, Soos S. Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases. *Biochim Biophys Acta.* (2008) 1797:128–72. doi: 10.1016/j.bbca.2008.09.014

Semple SC, Klimuk SK, Harasym TO, Dos Santos N, Ansell SM, Wong KF, et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor is fenestrated. *Int J Pharm.* (2019) 593:55–63. doi: 10.1016/j.ijpharm.2019.06.027

Khawar IA, Kim JH, Kuh HJ. Improving drug delivery to solid tumors: priming the tumor microenvironment. *J Control Release.* (2015) 180:71–89. doi: 10.1016/j.jconrel.2014.12.018

Robert Weiss, Pascale GE. Neovascularization induced by vascular endothelial growth factor is fenestrated. *Cancer Res.* (1997) 57:765–72.

Dvorak AM, Kohn S, Morgan ES, Fox P, Nagy JA, Dvorak HF. The vesiculo-vascular organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. *J Leukoc Biol.* (1996) 59:100–15. doi: 10.1002/jlb.59.1.100

Monsky WL, Fukumura D, Hiebauw AM, DeNeve RJ, Charnsangavej C, Tierney WM, Sabatini DM, Pardoll DM, Pardoll DM, et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. *Cancer Res.* (1999) 59:4129–35.

Kalyane D, Raval N, Maheshwari R, Tambe V, Kalia K, Tekade RK. Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. *Mater Sci Eng.* (2019) 98:1252–76. doi: 10.1016/j.msec.2019.01.066

Miao L, Lin CM, Huang L. Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. *J Control Release.* (2015) 219:192–204. doi: 10.1016/j.jconrel.2015.08.017
120. Mahmoudi M. Debugging nano-bio interfaces: systematic strategies to accelerate clinical translation of nanotechnologies. *Trends Biotechnol.* (2018) 36:755–69. doi: 10.1016/j.tibtech.2018.02.014

121. Serkova NJ. Nanoparticle-based magnetic resonance imaging on tumor-associated macrophages and inflammation. *Front Immunol.* (2017) 8:990. doi: 10.3389/fimmu.2017.00590

122. Daldup-Link H, Coussens LM. MR imaging of tumor-associated macrophages. *Oncoimmunology.* (2012) 1:507–9. doi: 10.4161/onci.19456

123. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. *N Engl J Med.* (2003) 348:2491–9. doi: 10.1056/NEJMoa022749

124. Heesakkers RA, Jager GJ, Hovels AM, de Hoop B, van den Bosch HC, Raat F, et al. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10–enhanced MR imaging. *Radiology.* (2009) 251:408–14. doi: 10.1148/radiol.2512071018

125. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. *Immunity.* (2010) 32:593–604. doi: 10.1016/j.immuni.2010.05.007

126. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. *J Clin Invest.* (2012) 122:787–95. doi: 10.1172/JCI59643

127. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. *Ann Rev Immunol.* (2009) 27:451–83. doi: 10.1146/annurev.immunol.021908.132532

128. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. *Cancer Cell.* (2014) 25:846–59. doi: 10.1016/j.ccr.2014.05.016

129. Kosoff D, Lang JM. Development and translation of novel therapeutics targeting tumor-associated macrophages. *Urol Oncol.* (2018) 37:556–62. doi: 10.1016/j.urolonc.2018.10.010

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2019 Hu, Guo, Xu, Wu, Huang, Yang, Xu, Wang and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*